Development of a Bridging ELISA for Detection of Antibodies Against ZV0203 in Cynomolgus Monkey Serum.
Tingting Liu,Yongliang Tong,Jinli Gao,Wenjing Fang,Junliang Wu,Xionghua Peng,Xiaotian Fan,Xiaoqiang Chen,Jianhua Sun,Sheldon Cao,Zhaohui Li,Likun Gong,Qiuping Qin,Dianwen Ju
DOI: https://doi.org/10.1016/j.vascn.2022.107210
IF: 2.285
2022-01-01
Journal of Pharmacological and Toxicological Methods
Abstract:Immunogenicity has been a major concern in the safety evaluation of therapeutic proteins. The assessment of the unwanted immunogenicity of the therapeutic proteins performed in animals prior to clinical trials has been a regulatory requirement. In preclinical studies of therapeutic proteins, cynomolgus monkeys are usually the most relevant animal species. ZV0203, a recombinant humanized anti-human epidermal growth factor receptor 2 monoclonal antibody covalently bound to a cytotoxic drug (Duo-5), possesses a novel format of antibody drug conjugates. In this study, we reported the development, validation, and application of a bridging enzyme-linked immunosorbent assay for the detection of antibodies against ZV0203 in cynomolgus monkey serum. Drug interference at low positive control (18.0 ng/mL) and high positive control (130 ng/mL) of anti-ZV0203 antibodies was not observed when ZV0203 concentration is below 1.74 mu g/mL and 1.49 mu g/mL, respectively. In addition, no interference was found from mouse IgG1, but interference was observed with human IgG1. No effect of hemolysis was found on the analysis results of the testing samples present in 100% pooled rabbit serum containing 2% (V/V) erythrocyte hemolysates. Besides, spiked anti-ZV0203 antibody in rabbit serum was stable after 5 freeze/thaw cycles. The results showed that the method is suitable for the detection of anti-ZV0203 antibodies in cynomolgus monkey serum. The assay was also successfully applied in the repeated dose study of ZV0203.